

Cindy Neunert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/839076/publications.pdf>

Version: 2024-02-01

29
papers

2,783
citations

687363

13
h-index

552781

26
g-index

30
all docs

30
docs citations

30
times ranked

2763
citing authors

#	ARTICLE	IF	CITATIONS
1	The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. <i>Blood</i> , 2011, 117, 4190-4207.	1.4	1,608
2	American Society of Hematology 2019 guidelines for immune thrombocytopenia. <i>Blood Advances</i> , 2019, 3, 3829-3866.	5.2	684
3	Multisystem Inflammatory Syndrome in Children Associated With Coronavirus Disease 2019 in a Children's Hospital in New York City: Patient Characteristics and an Institutional Protocol for Evaluation, Management, and Follow-Up. <i>Pediatric Critical Care Medicine</i> , 2021, 22, e178-e191.	0.5	98
4	Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1407-1413.	1.5	70
5	Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26736.	1.5	51
6	Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. <i>American Journal of Hematology</i> , 2019, 94, 741-750.	4.1	37
7	Second-line therapies in immune thrombocytopenia. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 698-706.	2.5	32
8	Physician decision making in selection of second-line treatments in immune thrombocytopenia in children. <i>American Journal of Hematology</i> , 2018, 93, 882-888.	4.1	30
9	Multicenter Cohort Study Comparing U.S. Management of Inpatient Pediatric Immune Thrombocytopenia to Current Treatment Guidelines. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1227-1231.	1.5	26
10	Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice. <i>Blood Advances</i> , 2019, 3, 1907-1915.	5.2	26
11	Autoimmune hemolytic anemia and immune thrombocytopenia following hematopoietic stem cell transplant: A critical review of the literature. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27569.	1.5	22
12	Immune thrombocytopenia: A review of upfront treatment strategies. <i>Blood Reviews</i> , 2021, 49, 100822.	5.7	19
13	Fatigue in children and adolescents with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2020, 191, 98-106.	2.5	18
14	Multisystem Inflammatory Syndrome Associated with COVID-19 Anti-thrombosis Guideline of Care for Children by Action. <i>Pediatric Cardiology</i> , 2021, 42, 1635-1639.	1.3	14
15	Maintenance rituximab for relapsing thrombotic thrombocytopenic purpura: a case report. <i>Transfusion</i> , 2019, 59, 921-926.	1.6	8
16	Clinical Characteristics and Quality of Life of Children with ITP Starting Second Line Treatments: Data from the ITP Consortium of North America ICON1 Study. <i>Blood</i> , 2016, 128, 249-249.	1.4	7
17	A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children. <i>Blood</i> , 2019, 134, 2369-2369.	1.4	7
18	Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing. <i>Blood</i> , 2015, 126, 73-73.	1.4	6

#	ARTICLE	IF	CITATIONS
19	Quality of life is an important indication for second-line treatment in children with immune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29023.	1.5	4
20	Length of Stay and Health Care Utilization Among Pediatric Autologous Hematopoietic Cell Transplantation Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 613.e1-613.e7.	1.2	3
21	Antifactor Xa Monitoring and Hematologic Complications of Pediatric Extracorporeal Membrane Oxygenation. <i>ASAIO Journal</i> , 2021, 67, 91-95.	1.6	3
22	SARS-CoV-2 vaccination in pediatric patients with immune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29760.	1.5	3
23	Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopenia (ITP) in children: study protocol. <i>BMJ Open</i> , 2021, 11, e044885.	1.9	2
24	Splenectomy for immune thrombocytopenia: the evolution and preservation of treatment. <i>Haematologica</i> , 2020, 105, 2507-2509.	3.5	2
25	Refractory autoimmune disease: an overview of when first-line therapy is not enough. <i>Seminars in Hematology</i> , 2016, 53, S35-S38.	3.4	1
26	Looking long-term: an unmet need in immune thrombocytopenia. <i>Lancet Haematology</i> , 2021, 8, e245-e246.	4.6	0
27	Physician Factors Determining Treatment Decisions in Selecting Second Line Agents for Pediatric ITP. <i>Blood</i> , 2016, 128, 1008-1008.	1.4	0
28	Comparison of Bleeding Tools in a Cohort of Pediatric Patients with ITP: Data from the Pediatric ITP Consortium of North America ICON1 Study. <i>Blood</i> , 2016, 128, 4752-4752.	1.4	0
29	Pediatric Heart Failure: Cardiac Ejection Fraction with Cardiomyopathy Decreased to 21% in Iron Deficient from 37% in Iron Sufficient Children. <i>Blood</i> , 2021, 138, 3077-3077.	1.4	0